Corresponding Author: Eduardo López-Medina, MD, MSc, Centro de Estudios en Infectología Pediátrica, Calle 5 B 5 No. 37 BIS-28, Cali, Colombia (email@example.com).
Accepted for Publication: February 18, 2021.
Published Online: March 4, 2021. doi:10.1001/jama.2021.3071
Author Contributions: Drs López-Medina and Ramirez had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: López-Medina, López, Hurtado, Dávalos, Ramirez, Martínez, Díazgranados, Oñate, Chavarriaga.
Acquisition, analysis, or interpretation of data: López-Medina, Hurtado, Ramirez, Martínez, Oñate, Chavarriaga, Herrera, Parra, Libreros, Jaramillo, Avendaño, Toro, Torres, Lesmes, Rios, Caicedo.
Drafting of the manuscript: López-Medina, Hurtado, Dávalos, Chavarriaga, Caicedo.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: López-Medina, Ramirez.
Obtained funding: López-Medina, López.
Administrative, technical, or material support: Hurtado, Dávalos, Martínez, Díazgranados, Chavarriaga, Herrera, Parra, Libreros, Jaramillo, Avendaño, Toro, Torres, Lesmes, Rios, Caicedo.
Supervision: López-Medina, López, Oñate, Rios, Caicedo.
Conflict of Interest Disclosures: Dr López-Medina reported receiving grants from Sanofi Pasteur, GlaxoSmithKline, and Janssen and personal fees from Sanofi Pasteur during the conduct of the study. Dr López reported receiving grants from Sanofi Pasteur, GlaxoSmithKline, and Janssen and personal fees from Sanofi Pasteur during the conduct of the study. Dr Oñate reported receiving grants from Janssen and personal fees from Merck Sharp & Dohme and Gilead outside the submitted work. Dr Torres reported receiving nonfinancial support from Tecnoquímicas unrelated to this project during the conduct of the study. No other disclosures were reported.
Funding/Support: This study received an unrestricted grant from Centro de Estudios en Infectología Pediátrica (grant ScDi823).
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: In addition to the authors, the following collaborators from Centro de Estudios en Infectología Pediátrica participated in the Estudio Para Evaluar la Ivermectina en COVID-19 (EPIC) trial:
Catalina De La Cruz, MD; Camilo Andrade; Iñigo Prieto, MD, MSc; Viviana Márquez, MD; Mary Luz Hernandez; Carlos Gonzalez, MD; Victoria Aguirre, RN; Gloria Tamayo; Leidy Gomez; Aracelly Romero; Socorro Mutis; Nidia Guaza; Eliana Valencia; James Riascos; Ovidio Maldonado; Laura Victoria, RN; Hilda Giraldo; Lina Solano, RN; Maria F. Collazos, RN; Elizabeth Toro, MD; Carlos Cortés, MD; Alexandra Sierra, MD; Carolina Ospina, MD; Diana P. Mazo, PharmD; Jhon J. Calderón; Jenny Yela, RN; Diego Rivera, RN; and Diana Suárez, PharmD.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We are grateful to the patients who participated in this trial; Erika Cantor, MSc, from the Institute of Statistics, Universidad de Valparaíso, Valparaíso, Chile, for her contribution during data analysis; Keith Veitch for his writing assistance; and Neal Alexander, PhD, from CIDEIM in Cali, Colombia, and Rodrigo DeAntonio, DrPH, from Cevaxin in Panamá City, Panamá, for their contribution during study planning. Ms Cantor and Mr Veitch received compensation for their roles in the study. Drs Alexander and DeAntonio did not receive compensation for their roles in the study. We thank Tecnoquímicas for its donation of the investigational product and placebo from August 26, 2020, until the end of the trial.
KM , Sivakumaran
H , Heaton
SM , Harrich
D , Jans
DA . Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J
. 2012;443(3):851-856. doi:10.1042/BJ20120150
E , Pezzullo
M , De Burghgraeve
et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother
. 2012;67(8):1884-1894. doi:10.1093/jac/dks147
A , Pagotto
R , Pórfido
et al. Ivermectin reduces coronavirus infection in vivo: a mouse experimental model. bioRxiv
. Preprint posted November 2, 2020. doi:10.1101/2020.11.02.363242
CD , Gottlieb
RL , Criner
et al; GS-US-540-5774 Investigators. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA
. 2020;324(11):1048-1057. doi:10.1001/jama.2020.16349
Z , McGoogan
JM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA
. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648
O , Corbacho-Monné
M , Ubals
et al; BCN PEP-CoV-2 RESEARCH GROUP. Hydroxychloroquine for early treatment of adults with mild COVID-19: a randomized-controlled trial. Clin Infect Dis
. 2020;ciaa1009.PubMedGoogle Scholar
M , Rayner
C , Noël
F , Jans
D , Wagstaff
K . Ivermectin and COVID-19: a report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses. Antiviral Res
. 2020;178:104805. doi:10.1016/j.antiviral.2020.104805
G , Momekova
D . Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnol Biotechnol Equipment
. 2020;34:469-74. doi:10.1080/13102818.2020.1775118
JC , Sherman
MS , Fatteh
N , Vogel
F , Sacks
J , Rajter
JJ . Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ICON Study. Chest
. Published online October 12, 2020. doi:10.1016/j.chest.2020.10.009Google Scholar
E , Hany
B , Abo Youssef
et al Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Research Square
. Preprint posted November 17, 2020. doi:10.21203/rs.3.rs-100956/v1Google Scholar
HA , Maulood
MF , Rasheed
AM , Fatak
DF , Kabah
KK , Abdulamir
AS . Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv
. Preprint posted October 27, 2020. doi:10.1101/2020.10.26.20219345Google Scholar
MS , Gheibi
N , Namdar
et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial. Research Square
. Preprint posted November 24, 2020. doi:10.21203/rs.3.rs-109670/v1Google Scholar
JA , Mejia-Fernandez
JL , Chan-Guevara
LS , Valencia-Artunduaga
MH , Costa
JL . Ivermectin as an adjunct in the treatment of refractory epilepsy [article in Spanish]. Rev Neurol
. 2017;65(7):303-310.PubMedGoogle Scholar
MR , Ochomo
EO , Aljayyoussi
et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis
. 2018;18(6):615-626. doi:10.1016/S1473-3099(18)30163-4